|
|
Article: Pro-Pharmaceuticals Announces Dosing of Patient with DAVANAT(R)/5-FU in Phase II Colorectal Cancer Trial at Ochsner Cancer Institute.
- Article from:
- Business Wire
- Article date:
- August 25, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEWTON, Mass. -- Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds that enable the targeted delivery of chemotherapy drugs to cancer cells, today announced the dosing of a colorectal cancer patient in a Phase II trial of its DAVANAT(R)/5-FU chemotherapy at Ochsner Cancer Institute in New Orleans, Louisiana. The Phase II trial is a third- or fourth-line therapy for metastatic colorectal cancer patients who have disease progression after receiving standard chemotherapeutic regimens. Ochsner Cancer Institute is the third Phase ll clinical site to begin dosing patients.
"Phase l clinical and pre-clinical studies have shown the ...